Sharemaestro company-news research for Merck & Company Inc (MRK), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NYSE
United States
Measured evidence
Company news sentiment
MRK news sentiment
Merck & Company Inc
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone66Neutral is 50
Constructive news tone
83/100 evidence confidence
100% direct company focus
17 current stories across 2 publishers
Current company news
Positive news being faded
Constructive news tone is drawn from 17 fresh independent stories, including 17 company-specific items across 2 publishers.
Latest source headline 5 Insightful Analyst Questions From Merck’s Q2 Earnings Call finance.yahoo.com · 12 Aug 2026 23:41What supports the read
17 current stories are mapped specifically to MRK.
Cross-story agreement is 85/100, indicating a comparatively coherent tape.
What tempers the read
Only 2 publishers currently contribute to the measured read.
Constructive headlines are not being rewarded by price, which raises a rejection flag.
66/100
Weighted toneConstructive news tone
83/100
Evidence confidencehigh confidence
100%/100
Company focus17 direct stories
85/100
Evidence agreement15/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth100
16.09 effective storiesSource breadth40
2 independent publishersDirect relevance100
company-specific evidence shareFreshness74
recency-weighted evidenceAgreement85
cross-story consistencySource independence21
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Constructive headlines are not being rewarded by price, which raises a rejection flag.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Sentiment confirms active trendPositive but stretched
News subjects
What is shaping the score
Earnings729 stories · 53%
Analyst action683 stories · 18%
Regulatory and legal673 stories · 18%
Market update672 stories · 12%
Source mix
Where the evidence comes from
finance.yahoo.com7314 stories · 82%
seekingalpha.com513 stories · 18%
Recurring subjects
Subjects appearing most often
Earnings8Biotech7Pharma6Price Target4Oncology4Healthcare4Guidance4Fda Approval4Clinical Trials4Vaccines2
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#185Tone
finance.yahoo.comDirect company coverage
5 Insightful Analyst Questions From Merck’s Q2 Earnings Call
5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic cancers and robust performance in Animal Health as core drivers. CFO Caroline Litchfield highlighted, "Our strong commercial and operational execution continues to drive near-term performance while we invest in our outstanding pipeline." While market reaction was muted, management acknowledg
Clinical TrialsEarningsGuidanceOncologyPharma
- Published
- 12 Aug 2026 23:41
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#267Tone
finance.yahoo.comDirect company coverage
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
- Published
- 12 Aug 2026 19:58
- Catalyst
- Analyst action
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#386Tone
finance.yahoo.comDirect company coverage
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio — including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy — is becoming central to top-line resilience. Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving r
Immuno OncologyOncologyPharmaRevenue Growth
- Published
- 12 Aug 2026 18:36
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#454Tone
seekingalpha.comDirect company coverage
U.K. regulator reaffirms safety of childhood vaccination
[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin
HealthcareRegulationSplitVaccines
- Published
- 12 Aug 2026 13:13
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#575Tone
finance.yahoo.comDirect company coverage
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target
Quick Read RVMD has surged 492% over one year on daraxonrasib's landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival. MRK ranks as the most likely acquirer, with Keytruda's patent cliff mounting pressure and CEO Robert Davis pledging to diversify its growth portfolio. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Revolution Medicines (NASDAQ:RVMD) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform
Balance SheetBiotechFda ApprovalM AOncologyPrice Target
- Published
- 12 Aug 2026 12:50
- Catalyst
- Analyst action
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#661Tone
finance.yahoo.comDirect company coverage
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More
Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price index will be released at the same time tomorrow. Economists forecast headline CPI to rise 0.1% month-over-month and 3.4% year-over-year, with core CPI expected to increase 0.2% month-over-month and 2.5% year-over-year. One thing is for sure; if the numbers come in hot and above expectations, the stock market could see a bout of heavy selling. All of the major ind
CryptoEarningsPrice TargetPrice TargetUpgrade Downgrade
- Published
- 12 Aug 2026 11:53
- Catalyst
- Analyst action
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#755Tone
finance.yahoo.comDirect company coverage
Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. The filings seek to broaden ENFLONSIA's indication in vulnerable pediatric groups where preventative options for RSV are limited. The dual U.S. and European regulatory milestones highlight Merck's efforts to build out its portfolio beyond oncology as attention on the future of Keytruda intensifies. For i
Fda ApprovalHealthcarePharmaVaccines
- Published
- 11 Aug 2026 18:14
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#880Tone
finance.yahoo.comDirect company coverage
MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?
Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as higher sales of oncology drugs, including Keytruda, and contributions from new products like Winrevair, Welireg, and Capvaxive, and the Animal Health segment were partially offset by lower sales of Gardasil and some other vaccines. Sales of blockbuster PD-L1 inhibitor Keytruda increased 4% to $8.4 billion. Merck also raised its 2026 revenue
AcquisitionsEarningsOncologyPatent ExpirationPharmaceuticalsRevenue Growth
- Published
- 11 Aug 2026 13:48
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#969Tone
finance.yahoo.comDirect company coverage
The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"
A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo "We are proud to recog
BiotechFda ApprovalPharmaceuticalsRare Diseases
- Published
- 11 Aug 2026 13:00
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1076Tone
finance.yahoo.comDirect company coverage
ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer
Suha Jhaveri, Bill Warren and Jim Wassil added to ILiAD Board of Directors; Antony Blanc appointed Chief Business Officer Appointments deepen vaccine development expertise and enhance global commercial and strategic leadership WESTON, Fla., August 11, 2026--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Officer at Vaxcyte; Suha Jhaveri, former Strategic Advisor at Cidara before its acquisit
BiotechClinical TrialsVaccine Development
- Published
- 11 Aug 2026 12:30
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1170Tone
finance.yahoo.comDirect company coverage
S&P 500 Companies' Quarterly Earnings Growth Eases Amid Healthcare Drop, Oppenheimer Says
S&P 500 companies' quarterly earnings growth rate eased from a week ago amid a drop in the healthcar PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in
Growth RateQuarterly Earnings
- Published
- 10 Aug 2026 18:02
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1274Tone
finance.yahoo.comDirect company coverage
Glioma Market is Set for Tremendous Growth at a CAGR of 15% During the Study Period (2022–2036), as Novel Targeted Therapies and Immunotherapies are Gaining Momentum | DelveInsight
DelveInsight Business Research LLP The glioma market is expected to witness steady growth over the coming years, driven by the rising incidence of primary brain tumors, increasing awareness, and advances in diagnostic technologies. The market is also benefiting from a robust pipeline of therapies, including Regorafenib (Bayer), AV-GBM-1 (Aivita Biomedical), Enzastaurin (DB-102) (Denovo Biopharma), Paxalisib (GDC-0084) (Kazia Therapeutics), and others, aimed at improving patient outcomes. New York, USA, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Glioma Market is Set for Tremendous Growth at a CAGR of 15
BiotechClinical TrialsFda ApprovalGliomaMarket Research ReportsPharma
- Published
- 10 Aug 2026 17:00
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1387Tone
finance.yahoo.comDirect company coverage
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The stock's shorter-term gains have been more modest, while valuation and weak Zacks Style Scores temper the case for simply extrapolating the recent move. IMCR's 3-Month Rally Puts Growth in Focus IMCR shares have climbed more than 20% over the past 12 weeks. That compares with gains of 6.4% over four weeks and 0.6% over one week, making the longer recent advan
BiotechClinical TrialsEarningsPrice Target
- Published
- 10 Aug 2026 16:16
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1434Tone
finance.yahoo.comDirect company coverage
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss
Immunocore Holdings plc IMCR posted second-quarter 2026 revenues of $115.9 million, up 18.3% year over year and above the Zacks Consensus Estimate of $114 million. The company's loss of 2 cents per share, however, was wider than the consensus estimate of a loss of 1 cent. Kimmtrak remained the central growth driver, while a temporary U.S. distributor stocking benefit complicates the third-quarter setup. Higher research spending and a sizable cash balance also frame the company's push to broaden its melanoma opportunity. IMCR's Q2 Sales Beat Shows Kimmtrak Strength Kimmtrak generated $74.9 mill
Consensus EstimateEarningsMelanomaPharmaRatings
- Published
- 10 Aug 2026 15:39
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1586Tone
finance.yahoo.comDirect company coverage
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. BMY Outperforms Industry, Sector & S&P 500 IndexZacks Investment Research Image Source: Zacks Investment Research The company reported better-than-expected second-quarter results on July 30, supported by robust demand for Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag. Results were also boosted by strong Eliquis performan
BiotechEarningsGeneric CompetitionGuidanceImmuno Oncology
- Published
- 10 Aug 2026 15:15
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1643Tone
seekingalpha.comDirect company coverage
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus
Wall Street’s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE
Consensus EstimateEarningsEarnings Per ShareGuidanceHealthcareM A
- Published
- 09 Aug 2026 13:05
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1757Tone
seekingalpha.comDirect company coverage
Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week
Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five consecutive sessions of losses. The State Street Health Care Select Sector SPDR ETF [https://seekingalpha.com/symbol/XLV] (XLV [https://seekingalpha.com/symbol/XLV]) rose 1.36% in the week so far. On a YTD basis, XLV has added more than 5%; however, it is lagging behind the broader S&P
BiotechEarningsEarnings NewsGuidanceHealthcarePharma
- Published
- 08 Aug 2026 15:15
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Earlier company news
MRK news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above.
The archive is starting now
Each successful collection will retain its qualifying headlines here instead of replacing the previous set.
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.